Alloy Therapeutics Inc., a biotechnology ecosystem company focused on democratizing access to advanced drug discovery technologies, has announced a strategic collaboration and licensing agreement with Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK). The partnership will aim to develop Takeda’s proprietary induced pluripotent stem cell (iPSC)-derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK). Alloy will play a key role in advancing the development of innovative therapies to combat both solid and hematological cancers.
Alloy Therapeutics has partnered with Takeda to develop the iCAR-T and iCAR-NK platforms, technologies originating from Takeda’s collaboration with the Center for iPS Research and Application (CiRA) at Kyoto University. iCAR-T technology aims to create ‘off-the-shelf’ cell therapies for cancer, offering improved potency and lower manufacturing costs compared to traditional autologous therapies. This collaboration will accelerate the development of iCAR-T and iCAR-NK for oncology applications, with Alloy gaining co-exclusive rights to commercialize these products.
Takeda’s Yasushi Kajii expressed confidence in Alloy’s flexibility and patient-centric approach, key factors in selecting Alloy as a partner. Alloy’s CEO, Errik Anderson, emphasized how the partnership aligns with their mission to enable rapid drug development and unlock the potential of iPSC-based therapies.
In support of the collaboration, Alloy is also establishing a Japanese subsidiary at Shonan Health Innovation Park in Kanagawa Prefecture to further advance the platform’s clinical validation and enhancements.
About Alloy Therapeutics
Alloy Therapeutics is a biotechnology ecosystem company focused on advancing drug discovery by democratizing access to innovative tools and technologies for therapeutic development. Its collaborative model spans academia, biotech, and pharma, offering resources across various biologic modalities to partners worldwide.
About Takeda
Takeda is a global biopharmaceutical company committed to improving health through transformative treatments, particularly in oncology, gastrointestinal diseases, rare diseases, and neuroscience. The company is dedicated to advancing patient care through a robust, R&D-driven pipeline.
